研究概要
我们的数据支持选择性PARP2抑制作为一种有前景的胰腺癌治疗策略,通过损害基因组完整性和增强抗肿瘤免疫反应,从而为对抗这一毁灭性疾病开辟潜在途径。
中文摘要
胰腺癌是最致命的肿瘤之一,其特征是免疫抑制性微环境和缺乏细胞毒性免疫细胞浸润,从而导致对免疫治疗耐药。在此,我们证明,在Myc驱动的胰腺癌小鼠模型中敲除聚(ADP-核糖)聚合酶2(PARP2)可延缓肿瘤进展并提高生存率。机制上,PARP2缺失可诱导与基因组不稳定性及复制应激相关通路的富集,导致γH2AX增加、染色体不稳定性及微核积累。除这些肿瘤内在效应外,PARP2缺失还可重塑肿瘤微环境,促进细胞毒性T细胞和NK 细胞浸润,同时减少免疫抑制性细胞群体,增强抗肿瘤细胞毒性。这些发现也在Kras G12D驱动的原位胰腺导管腺癌模型中得到重现。总体而言,我们的数据支持选择性PARP2抑制作为一种有前景的胰腺癌治疗策略,其通过损害基因组完整性并增强抗肿瘤免疫反应发挥作用,从而为对抗这一毁灭性疾病开辟了潜在途径。
展开英文摘要原文
Pancreatic cancer represents one of the most lethal tumors, characterized by an immunosuppressive microenvironment and a lack of cytotoxic immune cell infiltrates, which confer resistance to immunotherapy. Here, we demonstrate that deletion of poly(ADP-ribose) polymerase 2 (PARP2) in a Myc -driven mouse model of pancreatic cancer delays tumor progression and increases survival. Mechanistically, PARP2 loss induces enrichment of pathways associated with genomic instability and replicative stress, leading to increased γH2AX, chromosomal instability, and micronuclei accumulation. In addition to these tumor-intrinsic effects, PARP2 deletion reshapes the tumor microenvironment, promoting infiltration of cytotoxic T and natural killer cells while reducing immunosuppressive cell populations, enhancing antitumor cytotoxicity. These findings are recapitulated in a Kras G12D -driven orthotopic pancreatic ductal adenocarcinoma model. Collectively, our data support selective PARP2 inhibition as a promising therapeutic strategy for pancreatic cancer by impairing genome integrity and boosting antitumor immune response, thereby opening potential avenues for combating this devastating disease.
论文信息
- 作者
- Martínez-Bosch N、Manero-Rupérez N、Vázquez-Bellón N、Nickell-Hernández B、Ventura-Blanch C、Lutfi N、Lechuga CG、Martínez C
- 单位
- Cancer Research Program, Hospital del Mar Research Institute (HMRI), Unidad Asociada IIBB-CSIC, Barcelona, Spain.Spain
- 期刊
- Science advances2026 May 8